Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) FCF Margin (2016 - 2025)

Perspective Therapeutics' FCF Margin history spans 15 years, with the latest figure at 4274.27% for Q4 2024.

  • For Q4 2024, FCF Margin rose 411019.0% year-over-year to 4274.27%; the TTM value through Sep 2025 reached 14589.25%, down 1562872.0%, while the annual FY2024 figure was 1306.26%, 126912.0% up from the prior year.
  • FCF Margin for Q4 2024 was 4274.27% at Perspective Therapeutics, up from 12144.67% in the prior quarter.
  • Across five years, FCF Margin topped out at 4274.27% in Q4 2024 and bottomed at 12144.67% in Q3 2024.
  • The 5-year median for FCF Margin is 38.31% (2020), against an average of 421.71%.
  • The largest YoY upside for FCF Margin was 411019bps in 2024 against a maximum downside of -1177624bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 34.76% in 2020, then skyrocketed by 383bps to 98.26% in 2021, then crashed by -210bps to 107.92% in 2022, then surged by 252bps to 164.08% in 2023, then surged by 2505bps to 4274.27% in 2024.
  • Per Business Quant, the three most recent readings for CATX's FCF Margin are 4274.27% (Q4 2024), 12144.67% (Q3 2024), and 33.8% (Q2 2024).